HEPATOCELLULAR CARCINOMA

This study tested a method of delivering two chemotherapy drugs directly into the liver's artery for people with liver cancer that cannot be removed by surgery. The main goals were to see how long it took for tumors to grow after treatment, monitor side effects, and measure how l…

This study tested new immunotherapy drugs (nivolumab alone and combined with ipilimumab) for people with advanced liver cancer that could not be treated with surgery. It aimed to find safe doses and see if these drugs could shrink tumors and help patients live longer. The trial i…

This study tested if adding a direct liver chemotherapy infusion to a standard two-drug regimen (lenvatinib and a PD-1 inhibitor) works better for advanced liver cancer that has spread into a major vein. It involved 66 participants with this specific condition. The goal was to se…

This study tested a new drug called AK112 in patients with advanced liver cancer that could not be surgically removed. AK112 is designed to target two pathways involved in cancer growth at once. The main goals were to see if the drug was safe and if it could shrink tumors or stop…

This study tested how safe the drug cabozantinib is for people with advanced liver cancer that has spread or didn't respond to other treatments. It involved 110 patients who had already tried the standard drug sorafenib. The main goal was to see how well patients tolerated the dr…

This study tested a flexible dosing approach for delivering radiation beads (Y90 SIR-Spheres) directly to liver tumors that cannot be surgically removed. Researchers followed one patient to see if adjusting radiation doses based on individual tumor characteristics could improve t…

This study tested a new combination of two immunotherapy drugs (relatlimab and nivolumab) for people with advanced liver cancer that had worsened after standard pill-based treatments. The main goal was to see if the drug combo could shrink tumors and control the cancer. Researche…

This Phase 3 trial tested whether combining two established liver cancer treatments works better than using just one. Researchers compared standard chemoembolization (TACE) alone versus TACE followed by tumor ablation (RFA) in 242 patients with intermediate-stage liver cancer. Th…

This small, early-stage study tested whether combining two existing cancer drugs (alectinib and nivolumab) could help control advanced liver cancer that had stopped responding to standard treatments. It involved just 5 patients with recurrent or treatment-resistant liver cancer. …

This study tested a focused, high-dose radiation treatment for people with a single liver tumor who could not receive standard surgery or other therapies. 44 patients received three radiation sessions over 8-10 days using a precise machine called CyberKnife. The main goal was to …

This study tested whether a combination of two drugs, donafenib and an anti-PD-1 antibody, could safely prevent liver cancer from returning after surgery. It involved 30 patients who had their tumors removed but were at high risk of the cancer coming back. The goal was to see if …

This study tested whether combining two drugs, SHR-1210 (an immunotherapy) and apatinib (a targeted therapy), could help control advanced liver cancer. It involved 190 patients whose cancer had worsened or who could not tolerate the standard treatment. The goal was to see if this…

This study tested whether adding a new immunotherapy drug (SAR444245) to other standard cancer drugs could help control advanced cancers of the digestive system, including stomach, liver, and colon cancers. It involved 138 adults whose cancer had spread and was no longer respondi…

This study tested whether adding a new drug called SRF388 to a standard two-drug treatment could better control advanced liver cancer. It involved about 134 adults with newly diagnosed, inoperable liver cancer who had not yet received treatment. The main goals were to see if the …

This study aimed to find out if liver cancer patients still need surgery after their tumors disappear following initial drug and artery-based treatments. Researchers randomly assigned 74 patients whose tumors had vanished to either have surgery or be closely monitored without sur…

This study tested a new combination treatment for people with advanced liver cancer that had spread into a major vein in the liver. Researchers combined a targeted chemotherapy delivered directly to the liver with an immunotherapy drug designed to help the immune system fight can…

This completed Phase 3 study tested whether a new combination of two immunotherapy drugs (IBI310 and sintilimab) works better than the standard drug sorafenib for people with advanced liver cancer that cannot be removed by surgery. The trial involved 344 patients who had not rece…

This study looked at how well and how safely a newer combination drug treatment (Atezolizumab-Bevacizumab) works for advanced liver cancer in patients who also have liver scarring (cirrhosis), compared to an older type of drug (TKIs). Researchers followed 38 real-world patients t…

This study aimed to find the best length of immunotherapy treatment for people with advanced cancers. It enrolled 161 patients whose cancer had remained stable after one year of treatment. Researchers randomly assigned participants to either stop their immunotherapy or continue i…

This study tested whether using a special ultrasound technique could improve radiation treatment for liver cancer. Researchers gave patients an injection of tiny gas-filled bubbles and then used ultrasound to 'pop' them in the tumor area, hoping this would make the cancer cells m…

This study tested a new way to perform a standard liver cancer treatment. Doctors delivered chemotherapy beads directly to liver tumors through an artery in the wrist instead of the groin. The goal was to see if this approach was safe, effective, and led to fewer complications an…

This study tested whether combining two drugs, telatinib and Keytruda, could help control advanced stomach or liver cancers that had worsened after standard treatments. It involved 16 patients with these specific cancers. The main goal was to see how long the combination could ke…

This study tested whether giving the drug somatostatin after liver cancer surgery could prevent a serious complication called ascites, which is fluid buildup in the abdomen. It involved 179 patients with liver cancer and underlying liver disease who had surgery to remove part of …

This was a first-in-human study to test the safety and early effectiveness of a new drug called CHS-388 for people with advanced solid tumors. The trial enrolled 145 adults with cancers like kidney, liver, and lung cancer that had progressed after standard treatments. Researchers…

This large, completed Phase 3 study tested whether a drug called pembrolizumab could help prevent liver cancer (hepatocellular carcinoma) from returning in people who had their initial tumor completely removed by surgery or ablation. The study involved 959 participants who receiv…

This study tested whether measuring tiny molecules called microRNAs in blood could help detect liver cancer earlier in people with hepatitis C. Researchers compared blood samples from 84 participants including healthy people, hepatitis C patients, and those with liver cirrhosis o…

This study tested a new type of PET scan designed to better detect and locate gastrointestinal cancers. The scan uses a special tracer that attaches to a protein often found in these tumors. Researchers compared the scan results to tissue samples from 109 patients to see how accu…

This study tested a new type of imaging scan to see if it could better find and stage liver cancer. Researchers gave 52 patients a special radioactive tracer and then performed a combined PET/MRI or PET/CT scan. The goal was to see if this new scan method could improve upon curre…

This study aimed to find new markers in the blood that could help predict how well standard liver cancer treatments work. Researchers took blood samples from 17 patients before and after they received their normal treatments, like TACE or ablation. The goal was to see if certain …

This study aimed to gather more information about how well a specific biopsy needle works during a common diagnostic procedure. Doctors used the EchoTip AcuCore needle to collect tissue samples from 183 adults with various cancers or pancreatic conditions. The main goal was to se…

This study aimed to better understand the genetic and molecular characteristics of liver cancer (hepatocellular carcinoma). Researchers analyzed tumor samples from 808 patients to identify common genetic patterns and test a 'liquid biopsy' method using blood samples. The goal was…

This study aimed to discover biological markers that could predict how patients with advanced liver cancer respond to a specific drug combination. Researchers analyzed blood and tumor tissue samples from 166 patients who had already received the treatment. The goal was to find pa…

This study analyzed information from 19,019 liver cancer patients to understand if men and women have different risks of their cancer spreading. Researchers used national cancer database records and advanced computer programs to create separate prediction tools for each gender. T…

This study looked back at the medical records of 300 liver cancer patients treated in Brazilian hospitals between 2017 and 2022. The goal was to understand how liver cancer is typically managed in Brazil, what treatments patients receive, and how they fare over time. By analyzing…